FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Troendle August J.</u>				2. Issuer Name and Ticker or Trading Symbol Medpace Holdings, Inc. [ MEDP ]									k all app Direc	tor	<u>&gt;</u>	<b>(</b> 10% (	Owner		
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC. 5375 MEDPACE WAY				3. Date of Earliest Transaction (Month/Day/Year) 01/06/2021								X Officer (give title Other (specibelow)  President & CEO							
(Street) CINCINNATI OH 45227			4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	<b>,</b>						
(City)	(	State)	(Zip)																
		Та	ble I -	Non-Deriva	tive S	Secui	rities	Acc	quir	ed, D	isposed o	of, or E	Benefi	cially	/ Own	ed			
Date			2. Transaction Date (Month/Day/Ye	Execution Date		n Date,	Code (Instr.		ction	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								C	ode	v	Amount	(A) or (D)	Price		Transa	ransaction(s) nstr. 3 and 4)		r. 4)	(instr. 4)
Common	Stock			01/06/202	1			5	S <sup>(1)</sup>		91,667 <sup>(1)</sup>	D	\$140	.06(2)	6,57	77,420		I	By Medpace Investors, LLC <sup>(3)</sup>
Common Stock 01/07/2		01/07/202	1			5	S <sup>(1)</sup>		93,552(1)	D	\$140	.06(4)	6,483,868			I	By Medpace Investors, LLC <sup>(3)</sup>		
Common	Stock														70	6,643		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)  2. Conversion Date (Month/Day/Year) Price of Derivative Security  3. Transaction Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year)				. Deemed ecution Date, any	4. Transaction Code (Instr. 8)  5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3, and 5)		nber ative ities red sed	er 6. Date Ex Expiration (Month/Da		ercisable and Date	7. Titl Amor Secu Unde Deriv Secu	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
		Code	v	(A)	(D)	Dat Exe	e ercisabl	Expiration Date	Title	Number of Shares									

## **Explanation of Responses:**

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on December 3, 2020.
- 2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$140.00 to \$141.01. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$140.00 to \$141.425. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

/s/ Stephen P. Ewald, Attorney-in-Fact for August J. 01/08/2021 Troendle

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.